In 2011, the FDA approved vemurafenib, a selective oral BRAF-mutant inhibitor, for the treatment of unresectable or metastatic melanomas harbouring activated BRAFV600E mutations [9], as identified by Davies [74]. The gene discussed is BRAF; the disease is metastatic melanoma.